View clinical trials related to Pediatric Kidney Disease.
Filter by:The goal of this study is to learn if a clinical trial of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is possible in youth with chronic kidney disease (CKD). The investigators also plan to explore whether treatment with SGLT2i (Empagliflozin) helps improve risk factors for worsening kidney and heart disease. The main questions are: 1. Is enrolling 40 youth with CKD into a clinical trial of empagliflozin feasible (ie achievable)? 2. Does taking empagliflozin for 3 months result in positive changes in blood, urine, and heart function tests? Participants will be randomly selected (like flipping a coin) to either receive empagliflozin or not start treatment with empagliflozin and remain on their usual care. Study Procedures Include - For participants randomly selected for treatment, take empagliflozin once daily for 3 months - Phone calls with researchers every 2 weeks for check-ins - For participants taking empagliflozin, clinic visits 4 and 8 weeks after starting for check-ups and tests - All study participants will have clinic visits at the beginning and end (3 months) where researchers will collect information about their health and perform tests
The goal of this clinical trial is to test alpha lipoic acid in children undergoing hemodialysis. The main questions it aims to answer are: - Will the use of alpha lipoic acid lower cardiovascular events in that population? - Is the incidence of those cardiovascular events linked to the oxidative stress and endothelial dysfunction in that population? - Will the drug cause side effects? Participants will: - take either one dose daily of 600mg tablet Alpha lipoic acid orally or a look-alike tablet containing no drug. - be monitored for the occurrence of cardiovascular events (stroke, angina, etc.) - be monitored for the occurrence of side effects - give blood samples for testing serum levels of E-selectin biomarker and superoxide dismutase enzyme - undergo clinical examinations (Echocardiogram, Duplex ultrasonography, Intima-Media-Thickness) Researchers will compare between the group taking alpha lipoic acid and the group taking the look-alike tablet.